Blueprint Medicines Co. (NASDAQ:BPMC) Given Consensus Rating of “Hold” by Brokerages

Blueprint Medicines Co. (NASDAQ:BPMC) has been given a consensus recommendation of “Hold” by the fifteen brokerages that are covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, three have given a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $94.87.

Several analysts have recently weighed in on the stock. HC Wainwright lifted their target price on shares of Blueprint Medicines from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Friday. Citigroup upped their price objective on Blueprint Medicines from $65.00 to $76.00 and gave the company a “sell” rating in a research note on Friday. Wedbush restated an “outperform” rating and set a $110.00 target price on shares of Blueprint Medicines in a research report on Friday, April 26th. Stifel Nicolaus upped their price target on Blueprint Medicines from $120.00 to $130.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Finally, Piper Sandler increased their price objective on Blueprint Medicines from $78.00 to $104.00 and gave the stock a “neutral” rating in a research note on Friday.

Insider Activity at Blueprint Medicines

In other Blueprint Medicines news, COO Christina Rossi sold 6,070 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $90.69, for a total transaction of $550,488.30. Following the transaction, the chief operating officer now owns 64,306 shares of the company’s stock, valued at approximately $5,831,911.14. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Blueprint Medicines news, COO Christina Rossi sold 6,070 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $90.69, for a total value of $550,488.30. Following the transaction, the chief operating officer now directly owns 64,306 shares of the company’s stock, valued at $5,831,911.14. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jeffrey W. Albers sold 25,073 shares of the stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $87.28, for a total value of $2,188,371.44. Following the completion of the sale, the director now owns 176,050 shares of the company’s stock, valued at $15,365,644. The disclosure for this sale can be found here. Insiders sold a total of 92,289 shares of company stock valued at $8,314,163 over the last quarter. Corporate insiders own 3.88% of the company’s stock.

Institutional Investors Weigh In On Blueprint Medicines

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of Blueprint Medicines by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 6,114,970 shares of the biotechnology company’s stock valued at $564,045,000 after purchasing an additional 147,827 shares during the period. Wellington Management Group LLP lifted its stake in Blueprint Medicines by 3.2% in the 3rd quarter. Wellington Management Group LLP now owns 5,080,521 shares of the biotechnology company’s stock valued at $255,144,000 after acquiring an additional 156,807 shares in the last quarter. Rock Springs Capital Management LP grew its stake in shares of Blueprint Medicines by 22.8% during the 3rd quarter. Rock Springs Capital Management LP now owns 2,685,294 shares of the biotechnology company’s stock worth $134,855,000 after acquiring an additional 498,622 shares in the last quarter. Polar Capital Holdings Plc grew its stake in shares of Blueprint Medicines by 108.0% during the 3rd quarter. Polar Capital Holdings Plc now owns 1,040,000 shares of the biotechnology company’s stock worth $52,229,000 after acquiring an additional 540,000 shares in the last quarter. Finally, Avidity Partners Management LP raised its holdings in shares of Blueprint Medicines by 81.1% in the third quarter. Avidity Partners Management LP now owns 751,600 shares of the biotechnology company’s stock valued at $37,745,000 after purchasing an additional 336,600 shares during the last quarter.

Blueprint Medicines Price Performance

Shares of BPMC opened at $107.19 on Tuesday. The stock’s 50-day moving average price is $91.77 and its 200 day moving average price is $80.52. The company has a debt-to-equity ratio of 1.60, a quick ratio of 3.66 and a current ratio of 3.76. Blueprint Medicines has a 12-month low of $43.89 and a 12-month high of $110.93.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.04) by $0.22. Blueprint Medicines had a negative return on equity of 215.07% and a negative net margin of 102.15%. The business had revenue of $71.96 million for the quarter, compared to analysts’ expectations of $67.34 million. During the same period in the previous year, the business posted ($2.65) earnings per share. Blueprint Medicines’s quarterly revenue was up 85.5% on a year-over-year basis. On average, analysts predict that Blueprint Medicines will post -5.41 earnings per share for the current year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.